Continuous glucose monitoring for glycaemic control and cardiovascular risk reduction in patients with type 2 diabetes not on insulin therapy: A clinical trial
Authors' conclusion
Dexcom G6 CGM was associated with improved glycaemic control and cardiometabolic risk in patients with T2DM who were not on insulin. CGM can be a safe and effective tool to improve diabetes management in patients at high risk for adverse cardiovascular outcomes.
Study context
- Population
- Adults with T2D, HbA1c >7%, body mass index (BMI) ≥30 kg/m², not using insulin; 44% women, 34% Black, mean age 63 years, mean BMI 37 kg/m², HbA1c 8.4%, 10-year predicted ASCVD risk 24.0%
- Participants
- 47 adults
- Comparison
- Unblinded Dexcom G6 continuous glucose monitoring (CGM) vs blinded CGM with standard SMBG
- Outcome
- Glycaemic control (CGM metrics)
- Follow-up
- 90 days
Methodological detailstwo-phase cross-over, paired tests
- Two-phase cross-over
- Paired tests
Main finding
As reported in the abstract
Average glucose reduced (mg/dl)
184.0 to 147.2
p < .001
TIR increased (%)
57.8 to 82.8
p < .001
Trend towards lower glucose variability (%)
26.2 to 23.8
Further findings
Cardiometabolic risk factors and diabetes distress · 90 days
- Significant reductions in HbA1c, BMI, triglycerides, blood pressure, total cholesterol, diabetes distress and 10-year predicted ASCVD risk
- P < 0.05 for all
Prescriptions · 90 days
- SGLT2i prescriptions increased (%)
- 36.2 to 83.0
- GLP-1 RA prescriptions increased (%)
- 42.5 to 87.2
- P for both
- P < 0.001 for both
Original publication
Continuous glucose monitoring for glycaemic control and cardiovascular risk reduction in patients with type 2 diabetes not on insulin therapy: A clinical trial. Diabetes Obes Metab. Published 28 April 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →